PyL Imaging Agent Ably Detects Lesions Outside the Prostate, Phase 2/3 Trial Shows

PyL Imaging Agent Ably Detects Lesions Outside the Prostate, Phase 2/3 Trial Shows
PyL, a new imaging agent for positron emission topography (PET) scans, can accurately detect prostate cancer lesions outside the prostate, whether in nearby lymph nodes or in distant locations, clinical trial data show. The tracer — developed by Progenics — is a second generation fluorine-labeled small molecule that targets the prostate-specific membrane antigen (PSMA) protein, present at high levels in prostate cancer cells. Once bound to cancer cells, the radioactive fluorine serves as a signal for PET scans, making it possible to obtain an image showing the location of these cells. Results from a Phase 2/3 trial examining PyL's safety and accuracy were recently presented at the 2019  Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting in Anaheim, California. The oral presentation was titled “Results from the OSPREY trial: A PrOspective Phase 2/3 Multi-Center Study of 18F-DCFPyL PET/CT Imaging in Patients with PRostate Cancer - Examination of Diagnostic AccuracY.” The completed OSPREY Phase 2/3 trial (NCT02981368) included 385 men either with high-risk prostate cancer who had been referred for radical treatment — surgic
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *